A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Linagliptin (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms MARLINA; MARLINA-T2D
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
- 01 Aug 2021 Results of post hoc assessing urinary dipeptidyl peptidase-4 protein is increased by linagliptin and is a potential predictive marker of urine albumin-to-creatinine ratio reduction in patients with type 2 diabetes, analysis published in the Diabetes, Obesity and Metabolism.
- 05 Oct 2018 Results characterising the urinary proteomic profile (UPP) before and after treatment with linagliptin in T2D patients at early stages of DKD presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes